Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UKG1

UPID:
DP13A_HUMAN

ALTERNATIVE NAMES:
Adapter protein containing PH domain, PTB domain and leucine zipper motif 1

ALTERNATIVE UPACC:
Q9UKG1; Q9P2B9

BACKGROUND:
The multifunctional adapter protein, DCC-interacting protein 13-alpha, orchestrates a range of biological processes from cell proliferation and immune response to metabolism. It achieves this through interactions with RAB5A, the NuRD/MeCP1 complex, and APPL1, among others. Its role extends to modulating TLR4 signaling in macrophages and facilitating fibroblast migration via HGF signaling.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of DCC-interacting protein 13-alpha could open doors to potential therapeutic strategies, especially considering its involvement in Maturity-onset diabetes of the young 14, characterized by early-onset diabetes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.